Hyperkalemia
Research has begun to question recommendations to restrict potassium with CKD to manage hyperkalemia.
Researchers studied the prevalence of hyperkalemia in patients at a facility in Durban, South Africa.
Researchers reported on real-world use of SZC for hyperkalemia in a cohort of Asian hemodialysis patients.
Potassium adsorbents lower serum potassium levels but their effects on mortality and rehospitalization rates were unclear.
Researchers sought to determine the palatability of SZC, patiromer, and S/CPS in patients with CKD and hyperkalemia.
Experts developed consensus statements for management of hyperkalemia in the Asia–Pacific region.
The prevalence of hyperkalemia among individuals with chronic kidney disease (CKD) is 14% to 20%.
Examining the effects of finerenone doses in patients with chronic kidney disease (CKD) and type 2 diabetes.
When dietary potassium intake was examined within quartiles, there was a nonlinear association with AAC.
Both hyperkalemia and hypokalemia are associated with muscle paralysis and potentially fatal cardiac arrhythmias.
There are few data available on the adverse effect of hyperkalemia on progression of chronic kidney disease (CKD).
Patients with hyperkalemia treated with SCZ have a higher rate of continuation of RAAS inhibition.
Advertisement
Advertisement
